Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
FAQ
- What is Regeneron Pharmaceuticals's EBIT?
- Regeneron Pharmaceuticals (REGN) reported EBIT of $1.29B in Q2 2026.
- How has Regeneron Pharmaceuticals's EBIT changed year-over-year?
- Regeneron Pharmaceuticals's EBIT increased by 19.8% year-over-year, from $1.08B to $1.29B.
- What is the long-term trend for Regeneron Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's EBIT has grown at a -20.5% compound annual growth rate (CAGR), from $8.95B to $3.58B.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Regeneron Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude